ANAB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

87.26M

+102.4%

0.930

-229.11%

18.77M

-32.42%

-1.034

-19.22%

19.10M

-14.21%

-0.983

-26.62%

Estimates Revision

The market is revising Upward the revenue expectations for AnaptysBio, Inc. (ANAB) for FY2025, with the revenue forecasts being adjusted by 84.14% over the past three months. During the same period, the stock price has changed by 134.85%.

Revenue Estimates for FY2025

Revise Upward

+84.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-69.47%

In Past 3 Month

Stock Price

Go Up

+134.85%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast ANAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANAB is 68.57 USD with a low forecast of 50.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 45.560

Low

50.00

Averages

68.57

High

90.00

Current: 45.560

Low

50.00

Averages

68.57

High

90.00

Stifel

Buy

downgrade

$80 -> $56

2025-12-11

New

Reason

Stifel

Price Target

$80 -> $56

2025-12-11

New

downgrade

Buy

Reason

Stifel lowered the firm's price target on AnaptysBio to $56 from $80 and keeps a Buy rating on the shares. The firm "refreshed diligence" on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.

Barclays

Overweight

downgrade

$83 -> $70

2025-11-11

Reason

Barclays

Price Target

$83 -> $70

2025-11-11

downgrade

Overweight

Reason

Barclays lowered the firm's price target on AnaptysBio to $70 from $83 and keeps an Overweight rating on the shares. The firm says the pathogenic T-cell depletion did not translate to a benefit in ulcerative colitis. It cites the discontinuation of rosnilimab development in ulcerative colitis for the target cut.

H.C. Wainwright

Buy

downgrade

$59 -> $52

2025-11-11

Reason

H.C. Wainwright

Price Target

$59 -> $52

2025-11-11

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on AnaptysBio to $52 from $59 and keeps a Buy rating on the shares after the Phase 2 rosnilimab trial in ulcerative colitis does not meet the primary endpoint. The firm removed ulcerative colitis revenues from its model.

Wedbush

David Nierengarten

Outperform -> Outperform

downgrade

$70 -> $50

2025-11-10

Reason

Wedbush

David Nierengarten

Price Target

$70 -> $50

2025-11-10

downgrade

Outperform -> Outperform

Reason

Wedbush analyst David Nierengarten lowered the firm's price target on AnaptysBio to $50 from $70 and keeps an Outperform rating on the shares.

Stifel

Buy

maintain

$55 -> $80

2025-10-29

Reason

Stifel

Price Target

$55 -> $80

2025-10-29

maintain

Buy

Reason

Stifel raised the firm's price target on AnaptysBio to $80 from $55 and keeps a Buy rating on the shares. Phase 2 induction data for rosnilimab in UC due in November to December represents "the next major catalyst" for the company and the PD-1 agonist/depleter class, says the analyst, who thinks a signal in line with standard of care first-line biologics "would represent a clear win with potential to deepen over time" and thinks shares could trade to $70-$80 in such a scenario.

Wedbush

David Nierengarten

Outperform

maintain

$45 -> $70

2025-10-15

Reason

Wedbush

David Nierengarten

Price Target

$45 -> $70

2025-10-15

maintain

Outperform

Reason

Wedbush analyst David Nierengarten raised the firm's price target on AnaptysBio to $70 from $45 and keeps an Outperform rating on the shares. The firm notes that at an R&D Day, AnaptysBio detailed clinical development plans for CD122 antagonist mAb ANB033 in celiac disease, and highlighted a possible expansion into eosinophilic esophagitis. Importantly, the CeD trial will feature two cohorts: in addition to an expected cohort evaluating protection against gluten challenge, a second cohort will recruit patients with higher VH:CD ratios to test the ability of ANB033 to heal existing mucosal damage. Topline results are expected by year-end 2026, Wedbush adds.

Valuation Metrics

The current forward P/E ratio for AnaptysBio Inc (ANAB.O) is -21.50, compared to its 5-year average forward P/E of -3.90. For a more detailed relative valuation and DCF analysis to assess AnaptysBio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.90

Current PE

-21.50

Overvalued PE

2.51

Undervalued PE

-10.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.87

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.44

Undervalued EV/EBITDA

-7.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

29.30

Current PS

0.00

Overvalued PS

54.24

Undervalued PS

4.36

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ANAB News & Events

Events Timeline

No data

News

9.0

12-15PRnewswire

Vanda Submits BLA for Imsidolimab to Treat GPP

6.0

11-24Benzinga

Wedbush Affirms Outperform Rating for AnaptysBio, Keeps $50 Price Target Intact

2.0

11-21CNBC

Midday Stock Highlights: Notable Movements from Oracle, Bath & Body Works, Gap, and Others

People Also Watch

Frequently Asked Questions

What is AnaptysBio Inc (ANAB) stock price today?

The current price of ANAB is 45.56 USD — it has increased 1.38 % in the last trading day.

What is AnaptysBio Inc (ANAB)'s business?

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

What is the price predicton of ANAB Stock?

What is AnaptysBio Inc (ANAB)'s revenue for the last quarter?

AnaptysBio Inc revenue for the last quarter amounts to 76.32M USD, increased 154.26 % YoY.

What is AnaptysBio Inc (ANAB)'s earnings per share (EPS) for the last quarter?

AnaptysBio Inc. EPS for the last quarter amounts to 0.52 USD, decreased -145.61 % YoY.

What changes have occurred in the market's expectations for AnaptysBio Inc (ANAB)'s fundamentals?

How many employees does AnaptysBio Inc (ANAB). have?

AnaptysBio Inc (ANAB) has 136 emplpoyees as of December 16 2025.

What is AnaptysBio Inc (ANAB) market cap?

Today ANAB has the market capitalization of 1.24B USD.